TrialJournal of neuro-oncology2015
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
Andrew D Norden et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
42 papers cite it
this paperpooled ittrialcites it